Xtalks’ Post

Second big phase 2b study in which the safety and efficacy of the siRNA JNJ-3989 was evaluated in chronic hepatitis B patients

For decades, steroids have been considered a necessary evil to control ANCA-associated vasculitis. Yet today, more patients die from complications associated with glucocorticoid treatment than the underlying disease. Get a summary of the most comprehensive picture to date of evolving diagnostic and therapeutic strategies for this rare but devastating #AutoimmuneDisorder: https://hubs.li/Q02rhSdw0 #Vasculitis #AutoimmuneDiseaseManagement #SteritasGTI #SteroidToxicity #SteroidToxicityAwareness #VasculitisTreatment #SteroidInducedComplications

#infectionprevention #renalcare #clinicalresearch The first FDA-approved antimicrobial catheter lock solution CLS to prevent catheter-related bloodstream infections (CRBSIs) is: DefenCath® (taurolidine and heparin) acts by irreversible binding of its methylol groups to microbial cell walls and subsequent loss of cell wall integrity leading to cell death.

Interesting results from an emerging infections network survey about antifungal therapeutic drug monitoring practices. The abstract states, in a survey of 523 infectious disease specialists, a moderate to high percentage reported using any antifungal therapeutic drug monitoring (TDM) during itraconazole (72%), posaconazole (72%), and voriconazole (90%) treatment, and a low to moderate percentage reported using any antifungal TDM during prophylaxis (32%, 55%, and 65%, respectively). Long turnaround times for send-out TDM testing and logistical difficulties were frequent barriers. Read the full results now via OUP Academic: https://bit.ly/3FIX6db | #Antifungals #InfectiousDiseases #TherapeuticDrugMonitoring #PrecisionMedicine

Comparison of Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Treatment A retrospective analysis compared the effectiveness of tenofovir alafenamide

What is making me optimistic today FDA approves Regeneron's antibody for rare immune disease. The FDA approved Regeneron’s pozelimab, the first treatment for a rare, hereditary immune disease that affects fewer than 100 people worldwide. The monoclonal antibody, to be marketed as Veopoz, is expected to be made available to patients this quarter, a Regeneron spokesperson told Endpoints News. It’s cleared to treat adults and children 1 year and older with Chaple disease, a potentially life-threatening condition that often manifests in children and can cause severe gastrointestinal issues or blood clots. The wholesale acquisition cost is about $34,600 per single-use vial. The drug is taken weekly, though annual cost will vary depending on the patient’s weight. In setting the price, Regeneron said it “considered many factors including the new and significant advancement this medicine represented.” Pozelimab targets a protein called complement factor C5, which is involved in the activation of a part of the immune system called the complement system. “Beyond CHAPLE, we believe Veopoz has promise in a variety of complement-mediated diseases and are driving forward several clinical programs to explore its broader potential,” Regeneron president and CSO George Yancopoulos said in a news release.#immunsystem#immundisease#breakthrough#hope#optimistic https://lnkd.in/dr-vxHHp

For decades, steroids have been considered a necessary evil to control ANCA-associated vasculitis. Yet today, more patients die from complications associated with glucocorticoid treatment than the underlying disease. Get a summary of the most comprehensive picture to date of evolving diagnostic and therapeutic strategies for this rare but devastating #AutoimmuneDisorder: https://hubs.li/Q02qxYW20 #Vasculitis #AutoimmuneDiseaseManagement #SteritasGTI #SteroidToxicity #SteroidToxicityAwareness #VasculitisTreatment #SteroidInducedComplications

July 28th marks World Hepatitis Day, a global initiative to raise awareness about the pervasive yet often overlooked health challenge of hepatitis. Hepatitis, predominantly types B and C, affects millions globally, leading to chronic liver diseases and posing significant health threats. Efforts are amplified on this day to intensify prevention, testing, and treatment measures. The landscape of hepatitis treatment has transformed dramatically over the years. Innovative pharmaceuticals such as direct-acting antivirals (DAAs) have revolutionized hepatitis C treatment, boasting cure rates exceeding 90%. In the realm of hepatitis B, novel therapies such as RNA interference drugs are currently in clinical trials, demonstrating a promising future. On World Hepatitis Day, let's acknowledge the importance of continued research and innovation to tackle hepatitis effectively and work towards a hepatitis-free future. #WorldHepatitisDay #Hepatitis #Ipharma #Healthcare #PharmaceuticalInnovation

The Coalition for Global Hepatitis Elimination (CGHE) announces the publication of "Preferences and feasibility of long-acting technologies for treatment of hepatitis C virus in low- and middle-income countries: A survey of providers and policymakers" in the March Issue of the Journal of Viral Hepatitis. This study, led by Chief Technical Officer Neil Gupta of CGHE, delves into the acceptability and feasibility of long-acting technologies (LATs) for treating hepatitis C virus in low- and middle-income countries. Through surveys of HCV treatment prescribers and policymakers, the study illuminates the potential impact of LATs on enhancing linkage to care, treatment adherence, and outcomes in LMICs. Key findings reveal: ✔️ 93% of providers expressed willingness to prescribe LATs. ✔️ 72% of providers preferred LAT if provided at comparable efficacy, safety, and cost as current oral treatments. ✔️ Injection was the preferred LAT option among providers who favored LAT over daily oral medication. ✔️ Policymakers indicated a strong likelihood to incorporate LATs into treatment guidelines and national drug formularies if their efficacy, safety, and cost were comparable to oral treatments. These findings underscore the potential of HCV LATs to significantly contribute to progress toward HCV elimination in LMICs by offering a range of treatment options. Read the publication here: https://buff.ly/3PFYJxD

In December 2019, the outbreak of acute respiratory illness caused by a novel coronavirus (2019-nCoV) keeps spreading at a rapid pace around the world. Lack of an effective vaccine, repurposing inhibitors, or de novo drug design might provide a long-term plan to combat this and potential infections due to specific virus conditions. The emergence of highly contagious COVID-19 and its high mortality rate among human populations has recently been declared a deadly pandemic that has provoked economic chaos and severe health problems. SARS-CoV-2 is an essential virus within its proteome, with several druggable components. The disease is a worldwide health issue that is instigated by severe acute coronavirus-2 syndrome (SARS-CoV-2) in the respiratory system. It is therefore of interest to research the binding features of 1615 drugs with FDA approval on the newly discovered main protease structure of 2019 novel coronavirus having strong sequence homology to that of SARS-CoV. https://lnkd.in/gFQt4cEc